Literature DB >> 26410603

Outcomes and worsening renal function in patients hospitalized with heart failure with preserved ejection fraction.

Kavita Sharma1, Terence Hill1, Morgan Grams2, Natalie R Daya2, Allison G Hays1, Derek Fine2, David R Thiemann1, Robert G Weiss1, Ryan J Tedford1, David A Kass1, Steven P Schulman1, Stuart D Russell3.   

Abstract

Heart failure with preserved ejection fraction (HFpEF) has been described as a disease of elderly subjects with female predominance and hypertension. Our clinical experience suggests patients with HFpEF from an urban population are far more heterogenous, with greater co-morbidities and significant inhospital morbidity. There are limited data on the hospitalization course and outcomes in acute decompensated HFpEF. Hospitalizations for acute heart failure at our institution from July 2011 to June 2012 were identified by International Classification of Diseases, Ninth Revision, codes and physician review for left ventricular ejection fraction ≥50% and were reviewed for patient characteristics and clinical outcomes. Worsening renal function (WRF) was defined as creatinine increase of ≥0.3 mg/dl by 72 hours after admission. Hospital readmission and mortality data were captured from electronic medical records and the Social Security Death Index. Of 434 heart failure admissions, 206 patients (47%) with HFpEF were identified. WRF developed in 40%, the highest reported in HFpEF to date, and was associated with higher blood pressure and lower volume of diuresis. Compared to previous reports, hospitalized patients with HFpEF were younger (mean age 63.2 ± 13.6 years), predominantly black (74%), and had more frequent and severe co-morbidities: hypertension (89%), diabetes (56%), and chronic kidney disease (55%). There were no significant differences in 1- and 12-month outcomes by gender, race, or WRF. In conclusion, we found hospitalized patients with HFpEF from an urban population develop a high rate of WRF are younger than previous cohorts, often black, and have greater co-morbidities than previously described.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26410603     DOI: 10.1016/j.amjcard.2015.08.019

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  11 in total

Review 1.  How to Develop and Implement a Specialized Heart Failure with Preserved Ejection Fraction Clinical Program.

Authors:  Sanjiv J Shah; Rebecca Cogswell; John J Ryan; Kavita Sharma
Journal:  Curr Cardiol Rep       Date:  2016-12       Impact factor: 2.931

Review 2.  Heart failure with preserved ejection fraction: a nephrologist-directed primer.

Authors:  Baris Afsar; Patrick Rossignol; Loek van Heerebeek; Walter J Paulus; Kevin Damman; Stephane Heymans; Vanessa van Empel; Alan Sag; Alan Maisel; Mehmet Kanbay
Journal:  Heart Fail Rev       Date:  2017-11       Impact factor: 4.214

3.  Diastolic dysfunction predicts the risk of contrast-induced nephropathy and outcome post-emergency percutaneous coronary intervention in AMI patients with preserved ejection fraction.

Authors:  Beibei Han; Yongguang Li; Zhifeng Dong; Qing Wan; Hong Shen; Jingbo Li; Meng Wei; Chengxing Shen
Journal:  Heart Vessels       Date:  2018-04-27       Impact factor: 2.037

4.  Endomyocardial Biopsy Characterization of Heart Failure With Preserved Ejection Fraction and Prevalence of Cardiac Amyloidosis.

Authors:  Virginia S Hahn; Lisa R Yanek; Joban Vaishnav; Wendy Ying; Dhananjay Vaidya; Yi Zhen Joan Lee; Sarah J Riley; Vinita Subramanya; Emily E Brown; C Danielle Hopkins; Sandra Ononogbu; Kira Perzel Mandell; Marc K Halushka; Charles Steenbergen; Avi Z Rosenberg; Ryan J Tedford; Daniel P Judge; Sanjiv J Shah; Stuart D Russell; David A Kass; Kavita Sharma
Journal:  JACC Heart Fail       Date:  2020-07-08       Impact factor: 12.035

5.  Heart Failure Increases the Risk of Adverse Renal Outcomes in Patients With Normal Kidney Function.

Authors:  Lekha K George; Santhosh K G Koshy; Miklos Z Molnar; Fridtjof Thomas; Jun L Lu; Kamyar Kalantar-Zadeh; Csaba P Kovesdy
Journal:  Circ Heart Fail       Date:  2017-08       Impact factor: 8.790

6.  Galectin-3 and Risk of Heart Failure and Death in Blacks and Whites.

Authors:  John W McEvoy; Yuan Chen; Marc K Halushka; Eric Christenson; Christie M Ballantyne; Roger S Blumenthal; Robert H Christenson; Elizabeth Selvin
Journal:  J Am Heart Assoc       Date:  2016-05-13       Impact factor: 5.501

7.  Cardiac Microvascular Endothelial Enhancement of Cardiomyocyte Function Is Impaired by Inflammation and Restored by Empagliflozin.

Authors:  Rio P Juni; Diederik W D Kuster; Max Goebel; Michiel Helmes; René J P Musters; Jolanda van der Velden; Pieter Koolwijk; Walter J Paulus; Victor W M van Hinsbergh
Journal:  JACC Basic Transl Sci       Date:  2019-09-04

8.  Myocardial Gene Expression Signatures in Human Heart Failure With Preserved Ejection Fraction.

Authors:  Virginia S Hahn; Hildur Knutsdottir; Xin Luo; Kenneth Bedi; Kenneth B Margulies; Saptarsi M Haldar; Marina Stolina; Jun Yin; Aarif Y Khakoo; Joban Vaishnav; Joel S Bader; David A Kass; Kavita Sharma
Journal:  Circulation       Date:  2020-10-29       Impact factor: 29.690

Review 9.  Clinical Phenotypes in Heart Failure With Preserved Ejection Fraction.

Authors:  Rohan Samson; Abhishek Jaiswal; Pierre V Ennezat; Mark Cassidy; Thierry H Le Jemtel
Journal:  J Am Heart Assoc       Date:  2016-01-25       Impact factor: 5.501

Review 10.  Targeting Obesity and Diabetes to Treat Heart Failure with Preserved Ejection Fraction.

Authors:  Raffaele Altara; Mauro Giordano; Einar S Nordén; Alessandro Cataliotti; Mazen Kurdi; Saeed N Bajestani; George W Booz
Journal:  Front Endocrinol (Lausanne)       Date:  2017-07-17       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.